Rohto Pharmaceutical Overview and Company Profile

Rohto Pharmaceutical is a Japanese company with a rich history dating back to 1899. It was founded by a Japanese pharmacist named Shigeru Hayashi.

Rohto Pharmaceutical is headquartered in Osaka, Japan, and has a presence in over 30 countries worldwide. This global reach allows the company to distribute its products to a diverse range of customers.

The company's name "Rohto" is derived from the Japanese word for "eye drops", which was one of the company's first products.

Rohto Pharmaceutical Co., Ltd is a multinational company with a history spanning over 120 years.

Headquartered in Osaka, Japan, the company has various domestic and overseas subsidiaries.

Rohto was initially known for its OTC drugs, but it has since diversified its business to pursue other ventures for the well-being of people and society.

The company's core is centered around meeting and exceeding customer expectations, a motivator that has guided Rohto throughout its history.

A different take: Wells Fargo Bank History

Rohto's Management Vision 2030 aims to strengthen core areas by 2030.

The company's spirit is reflected in its motto "NEVER SAY NEVER", which drives it to strive for making every individual and society healthier.

A diverse workforce is essential to Rohto, as it believes that people from different backgrounds bring unique experiences, points of view, and knowledge that maximize creativity and accelerate innovation.

The company's way of working is characterized by close cooperation, taking challenges, and being action-oriented.

Rohto Pharmaceutical Co Ltd has a commercialized product portfolio that's worth exploring to stay ahead of the market.

Their marketed drugs are a key part of this portfolio, and understanding what they are can help you navigate the industry.

One way to contend with shifting product portfolios is to identify which of Rohto Pharmaceutical Co Ltd’s products will be commercialized.

This can give you a competitive edge and help you stay one step ahead of the market.

Suggestion: One Swiss Bank

Rohto Pharmaceutical is a Japanese company with a rich history dating back to 1892. It was founded by Dr. Ryoji Yokokura as a small pharmacy in Osaka.

The company's early success was driven by its innovative products, including eye drops and ointments. Rohto's eye drops, in particular, quickly gained popularity for their effectiveness in relieving eye irritation and dryness.

Today, Rohto Pharmaceutical is a leading manufacturer of eye care products, as well as other pharmaceuticals and cosmetics.

Business Overview is all about understanding the fundamental aspects of a company. A business overview typically includes a company's mission statement, which is a statement that defines the company's purpose and goals.

The company's mission statement is often found in the "Mission and Vision" section of the business overview. For example, a company's mission statement might be to "provide high-quality products to customers while maintaining a commitment to sustainability."

A company's vision statement, on the other hand, is a statement that describes what the company wants to achieve in the future. This can be found in the "Mission and Vision" section as well. A company's vision statement might be to "become the leading provider of sustainable products in the industry within the next five years."

On a similar theme: Brookfield Business Partners

A business overview also typically includes information about the company's products or services, which can be found in the "Products and Services" section. This section should provide a detailed description of what the company offers and how it differs from its competitors.

The company's target market is also an important aspect of the business overview, which can be found in the "Target Market" section. This section should describe the specific group of customers that the company is trying to reach with its products or services.

For another approach, see: Tempus Ai Company Overview

Rohto Pharmaceutical Co.,Ltd. has a significant presence in the Japanese market, with sales reaching 164 billion yen in 2025, up from 115 billion yen in 2021.

Their sales in Japan have been steadily increasing, growing by 14% from 2021 to 2022 and another 13% from 2022 to 2023.

In contrast, sales in China have been relatively stable, growing by 25% from 2021 to 2022, but only by 13% from 2022 to 2023, reaching 45.87 billion yen in 2025.

Their sales in other regions, including Asia (excluding Japan and China), have been increasing rapidly, growing by 19% from 2021 to 2022 and another 32% from 2022 to 2023.

Here's a breakdown of Rohto Pharmaceutical Co.,Ltd.'s sales by geography:

Rohto Pharmaceutical Co., Ltd. reported consolidated sales of approximately ¥145.1 billion for the fiscal year ending March 2023, reflecting a year-on-year growth of 6.3%.

This significant revenue growth can be attributed to the company's diverse portfolio of consumer healthcare products, pharmaceuticals, and cosmetics. The segment breakdown shows that OTC drugs accounted for roughly 50% of total sales, while consumer health and skincare segments contributed 30% and 20%, respectively.

Here's a breakdown of Rohto's sales by segment:

Rohto's international business has also seen significant growth, contributing around 25% to its total revenue, with notable sales in Asia, North America, and Europe.

Rohto Pharmaceutical Co., Ltd. is a publicly traded company listed on the Tokyo Stock Exchange under the ticker symbol 4527. As of September 2023, its market capitalization stands at approximately ¥463.5 billion (around $3.1 billion).

The company's ownership structure is dispersed, reflecting the common structure seen in many Japanese firms. Institutional investors hold significant stakes, with Japan Trustee Services Bank, Ltd. being the largest shareholder at 7.23%. Other notable institutional investors include The Master Trust Bank of Japan, Ltd. and Shinsei Bank, Limited.

Rohto Pharmaceutical's largest shareholders include institutional investors and notable individuals. The breakdown of major shareholders is as follows:

Our organization has a presence in several locations across Japan.

We have a primary office located at 1-8-1, Tatsuminishi, Ikuno-ku, Osaka, Osaka 544-8666, JP.

You can also find us at 3-1, Ofuka-cho, Kita-ku, Osaka, Osaka 530-0011, JP.

Additionally, we have a location at 1-2-20, Kaigan, Minato-ku, Tokyo 105-0022, JP.

Here are our main locations:

The Board of Directors plays a crucial role in overseeing the strategic direction of Rohto Pharmaceutical Co.,Ltd. Kunio Yamada serves as the Chairman of the Board, a position he has held since 2009.

The Board is composed of eight members, including Shinichi Kunisaki, Masaya Saito, Haruka Mera, Akie Iriyama, Eriko Hayashi, Yasunori Kawasaki, Masae Yamanaka, and Noriko Suenobu. Each member brings their unique expertise and experience to the table.

Here's a breakdown of the Board members:

The Board members have a wide range of experience and expertise, with some having been with the company for over a decade.

Rohto Pharmaceutical Co., Ltd. is a publicly traded company listed on the Tokyo Stock Exchange under the ticker symbol 4527. As of September 2023, its market capitalization stands at approximately ¥463.5 billion, or around $3.1 billion.

The company has a dispersed ownership structure, which is common in many Japanese firms. Institutional investors hold significant stakes, with Japan Trustee Services Bank, Ltd. owning 7.23% of the company, and The Master Trust Bank of Japan, Ltd. owning 5.51%.

Rohto Pharmaceutical's largest shareholders are institutional investors. The top five shareholders are:

Individual investors also hold significant stakes in the company. Haruhiko Hoshino, an individual, owns 2.80% of Rohto Pharmaceutical.

Rohto Pharmaceutical Co., Ltd. has a mission statement that's all about enhancing the quality of life through innovative healthcare solutions. Their mission is encapsulated in their slogan, "The Joy of Health", which reflects their dedication to providing accessible healthcare solutions.

The company was established in 1899 and has been a major player in the pharmaceutical and healthcare industry ever since. They've grown significantly, with consolidated net sales of ¥153.7 billion (approximately $1.15 billion) in the fiscal year ending March 31, 2023.

Expand your knowledge: Better Online Solutions

Rohto's commitment to innovation is evident in their research and development efforts. In 2023, they allocated 5.3% of total sales to R&D, which has enabled them to expand their product offerings in areas like over-the-counter medications, personal care products, and health supplements.

Here's a breakdown of Rohto's financial performance over the past few years:

Rohto's international presence is another key aspect of their mission. They operate in over 20 countries and have seen their international sales grow to represent approximately 30% of total revenue in recent years.